FCRL2 and B-cell chronic lymphocytic leukemia: An analysis of FCRL1–5 in a cohort of CLL patients well-characterized for standard prognostic factors, identified FCRL2 as a marker for a subgroup of CLL patients with a more indolent disease course as reflected by favorable progression free survival and overall survival (34, 35).